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Aims: The AleCardio trial aimed to characterize the efficacy and safety of peroxisome
proliferator-activated receptor-αγ agonist aleglitazar in patients with type 2 diabetes
mellitus and acute coronary syndrome. The trial terminated early because of futility
and safety signals. We evaluated whether the safety signals could be attributed to
increased exposure to aleglitazar.
Materials and Methods: The AleCardio trial enrolled 7226 patients to receive aleglitazar
150 μg or matching placebo on top of standard care. A population pharmacokinetic anal-
ysis was conducted in a pharmacokinetic substudy to identify covariates that explained
interindividual variability in exposure. Subsequently, the effect of these covariates on sur-
rogate and clinical outcomes was assessed in the full patient population.
Results: Concomitant administration of clopidogrel was identified as a covariate that
influenced the apparent clearance of aleglitazar. Patients using clopidogrel had a
mean predicted area under the plasma-concentration-time curve (AUC0–24) of
174.7 ng h/mL (SD: ±112.9 ng h/mL) versus 142.2 ng h/mL (SD: ±92.6 ng h/mL) in
patients without clopidogrel. The effect of aleglitazar compared with placebo on
HbA1c, haemoglobin, serum creatinine and adiponectin was modified by concomitant
clopidogrel use (P for interaction 0.007, 0.002, <0.001 and < 0.001, respectively).
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Conclusions: Concomitant use of clopidogrel was identified as a covariate that
explained interindividual variability in exposure to aleglitazar. Patients using
clopidogrel showed an additional lowering of HbA1c, at the expense of an additional
decrease in haemoglobin, and an increase in serum creatinine and adiponectin.
Clopidogrel is a moderate inhibitor of CYP2C8. Because aleglitazar is metabolized by
CYP2C8, a pharmacokinetic interaction could explain differences in exposure and
response to aleglitazar.
K E YWORD S
aleglitazar, exposure response, peroxisome proliferator-activated receptor, PK-PD, randomized
controlled trial
1 | INTRODUCTION
Peroxisome proliferator-activated receptor (PPAR)-γ receptors regu-
late glucose homeostasis, insulin sensitivity and lipid storage while
PPAR-α receptors regulate fatty acid β-oxidation and energy homeo-
stasis. Aleglitazar is a dual agonist of the PPAR-α and -γ receptors and
has been shown to improve glycaemic variables and lipid profile in
patients with type 2 diabetes mellitus.1,2 However, PPAR-γ activation
may lead to sodium and fluid retention, particularly in patients with
type 2 diabetes who are prone to sodium and fluid retention.3
The AleCardio trial was designed to determine whether aleglitazar
compared with placebo reduces cardiovascular morbidity and mortal-
ity among patients with type 2 diabetes mellitus and a recent acute
coronary syndrome (ACS).4 The trial was terminated early because of
futility for efficacy and increased rates of congestive heart failure,
bone fractures and gastrointestinal haemorrhage associated with
aleglitazar.5 The increased rate of congestive heart failure is probably
a result of sodium and fluid retention following PPAR-γ activation.
Patients assigned to aleglitazar received a fixed dose of 150 μg
daily. It is unknown whether increased exposure to aleglitazar contrib-
uted to the safety findings in the trial. The aim of the current study
was therefore to characterize the interindividual variation in exposure
to aleglitazar, to determine the factors associated with aleglitazar
exposure, and to assess the association between aleglitazar exposure
and safety and efficacy measures.
2 | MATERIALS AND METHODS
2.1 | Study design and patient population
The design of the AleCardio trial (Clinicaltrials.gov trial registration
number: NCT01042769; registration date: January 6, 2010) has been
reported previously.4,5 The study protocol of the AleCardio trial was
approved by the appropriate national and institutional regulatory and
ethical boards.
Briefly, qualifying patients were hospitalized for ACS (defined as
unstable angina or acute myocardial infarction) with established or
newly diagnosed type 2 diabetes mellitus. Exclusion criteria included
symptomatic heart failure or hospitalization with a primary diagnosis
of heart failure within the previous year, severe peripheral edema, an
estimated glomerular filtration rate (eGFR) of less than
45 mL/min/1.73 m2, or treatment with another PPAR agonist. A total
of 7226 patients at 720 sites in 26 countries were enrolled between
February 2010 and May 2012. Between hospital discharge after ACS
and 12 weeks thereafter, patients were randomized in a double-blind,
1:1 ratio to receive aleglitazar (150 μg per day) or matching placebo
on top of standard therapy. Patients were asked to take study medica-
tion at the same time of the day throughout the study, but a specific
time of day or relation to meals was not specified. The primary effi-
cacy endpoint was time to cardiovascular death, non-fatal myocardial
infarction, or non-fatal stroke. Principal safety endpoints were hospi-
talization caused by heart failure and changes in renal function. Effi-
cacy measures and hospitalization for heart failure were adjudicated
by a blinded clinical events committee. Other adverse events of spe-
cial interest were edema, bone fractures, hypoglycaemia and malig-
nancies. Upon the recommendation of the data and safety monitoring
board, the trial was terminated in July 2013 with a median follow-up
of 2 years because of futility for efficacy and increased rates of safety
endpoints with aleglitazar.
In a pharmacokinetic substudy, plasma samples were collected in
515 of 3616 patients treated with aleglitazar. In this substudy,
patients were divided into two groups with different pharmacokinetic
sampling schemes. In the first group (n = 117), a total of four samples
were collected at predose and between 30–120, 121–180 and
181–240 minutes after administration of aleglitazar at a single study
visit. In the second group (n = 398), again a total of four samples were
collected; however, in this group a sample was collected predose and
postdose at two consecutive study visits. For the purpose of analysis,
data of both groups were pooled. Actual dosing times and sampling
times were recorded. Pharmacodynamic samples were collected for all
patients throughout the AleCardio trial at multiple study visits.
2.2 | Population pharmacokinetic analysis
A stepwise approach was used to develop the pharmacokinetic model.
Different structural models with linear absorption and elimination
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processes were explored, including one- and two-compartment
models. Parameter estimates were obtained using first-order condi-
tional estimation with interaction. Interindividual variability (IIV) was
incorporated in the model, assuming a log-normal distribution of the
random effects on the model parameters. Also, covariance between
random effects was formally tested. Additive, proportional and combi-
nation residual variability models were tested. Covariate screening
was performed for the following covariates: eGFR at baseline, body
weight (at baseline and time-dependent), use of different types of co-
medication at baseline, occasion of study visit, food effect (fasted
vs. non-fasted state), age, sex, race, ethnicity and smoking status (both
smoking at baseline and duration of smoking). Covariates were
explored using correlation matrices of the empirical Bayes estimates
of the parameters versus potential covariates. Significant covariates
(P < 0.05) were taken forward in the model development. Continuous
covariates were modelled as log-normal distributed, median-
normalized covariates. For discrete covariates, separate population
parameters were estimated. For body weight, allometric scaling with
and without fixed power coefficients was explored.6 Model selection
and evaluation was based on the minimum objective function value
(MOFV), standard goodness-of-fit plots, residual standard error (RSE)
of the population parameter estimates and the coefficient of variation
(CV) of the interindividual random effects.6
2.3 | Pharmacodynamic analysis
2.3.1 | Surrogate outcomes
After the population pharmacokinetic analysis, we investigated the
exposure-response relationship between aleglitazar and several surro-
gate outcomes. Not only the patients included in the pharmacokinetic
substudy, but all patients included in the AleCardio trial were evalu-
ated. HbA1c, the primary efficacy risk marker, haemoglobin and body
weight, proxies for sodium retention, and serum creatinine,
adiponectin and triglycerides, were included in the exposure-response
analysis. At first, for each of these surrogate outcomes, change of
baseline over time was explored graphically. Second, patients were
stratified based on covariates, identified in the population pharmaco-
kinetic analysis, which were able to explain variability in exposure to
aleglitazar. Continuous and discrete covariates required a different
approach. For discrete covariates, patients were stratified per treat-
ment arm, placebo or aleglitazar, and per covariate. For continuous
covariates, patients were stratified per treatment arm and per quartile
of the covariate. Third, a one-way analysis of covariance (ANCOVA)
model was used to compare the effect of aleglitazar versus placebo
per group. To determine if the aleglitazar treatment effect was modi-
fied by the covariate of interest, an interaction term between treat-
ment group and the covariate of interest was added to the ANCOVA
model. It was assumed that the effect of aleglitazar on cardiovascular
risk markers was maximal after 6 months of treatment.4 Therefore, in
the ANCOVA analysis, initial change from baseline until month 6 was
used. Treatment arm and covariate stratum were included as fixed
effects.
2.3.2 | Clinical outcomes
The effects of covariates that influenced exposure were further
explored on hard outcomes that caused the early termination of the
AleCardio trial. The safety measures—hospitalization for heart failure,
gastrointestinal haemorrhage and bone fractures—were evaluated
using Cox proportional hazard models. All patients were stratified
based on the approach described under surrogate outcomes. Treat-
ment, covariate stratum and the interaction between treatment and
covariate stratum were included in the models. Hazard ratios including
95% confidence intervals were estimated for all patients and for the
stratified patient populations.
All data preparation and presentation was performed using R ver-
sion 3.2.3 (R Foundation for Statistical Computing, Vienna, Austria).
The population pharmacokinetic analysis was conducted using NON-
MEM version 7.3.0 (ICON Development Solutions, Ellicott City, MD,
USA). The ANCOVA and Cox-proportional hazard models were per-
formed in R, using the car package version 2.1.6 and survival package
version 2.41–3, respectively.
3 | RESULTS
3.1 | Population pharmacokinetic analysis
In total, 1855 plasma samples collected from 514 patients in the
aleglitazar group were used for the pharmacokinetic analysis. Of
these, 94 samples were excluded based on concentration below the
lower limit of quantification (n = 59), insufficient volume to assay the
sample (n = 13), missing dosing information (n = 23) and erroneous
randomization to placebo instead of aleglitazar (n = 1). This resulted in
the inclusion of 1761 samples from 514 patients, with one to four
samples per patient. Most plasma samples were drawn 0–4 hours
postdose (n = 1005) and most of the predose samples (n = 693) were
drawn at least 20 hours after the preceding dose. The demographics
of the patients included in the population pharmacokinetic analysis
are presented in Table 1.
An exploratory analysis was conducted to summarize and visualize
the measured concentrations of aleglitazar. The observed concentra-
tions of aleglitazar were variable and covered a concentration range
of 0.1 to 60.1 ng/mL at steady state (Figure 1). A two-compartment
model best described the data of the pharmacokinetic substudy. IIV
could be identified on both apparent clearance (CL/F) and apparent
volume of distribution (V2/F) and a proportional residual error model
proved to be best fit for purpose. A food effect on the absorption rate
constant (KA) and concomitant administration of clopidogrel on CL/F
improved model fit significantly (P < 0.05). Allometric scaling with
fixed power coefficients improved goodness-of-fit plots and was
therefore included in the model.
In general, the individual trend of the data is well captured by the
population pharmacokinetic model. Goodness-of-fit plots are pro-
vided in Figure S1 and parameter estimates are tabulated in Table 2.
The goodness-of-fit plots indicated that the high concentrations
appear to be slightly underestimated. However, population parameter
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estimates were estimated with high precision as indicated by their low
RSE, ranging from 4.2%–19.0%. The CV of CL/F was 57.1% with low
shrinkage (6%). The CV for the IIV on V2/F was high (587%) with
accompanying high shrinkage (37%). As inclusion of IIV on the V2/F
improved the individual fit of the data in terms of MOFV, residuals
and goodness-of-fit plots, it was decided to include this random effect
TABLE 1 Baseline characteristics of patients included in the AleCardio trial
Pharmacokinetic analysis Pharmacodynamic analysis
With clopidogrel Without clopidogrel All With clopidogrel Without clopidogrel All
Number of patients 420 94 514 5952 1274 7226
Age (years) 60.3 (9.5) 59.5 (10.5) 60.1 (9.7) 60.9 (10.0) 60.3 (9.7) 60.8 (10.0)
Sex (males) 324 (77.1) 62 (66.0) 386 (75.1) 4331 (72.8) 929 (72.9) 5260 (72.8)
Smoker 90 (21.4) 14 (14.9) 104 (20.2) 1281 (21.5) 203 (15.9) 1484 (20.5)
Race
African American 7 (1.7) 8 (8.5) 15 (2.9) 158 (2.7) 65 (5.1) 223 (3.1)
Asian 99 (23.6) 21 (22.3) 120 (23.3) 1716 (28.8) 168 (13.2) 1884 (26.1)
Caucasian 302 (71.9) 64 (68.1) 366 (71.2) 3855 (64.8) 963 (75.6) 4818 (66.7)
Other 12 (2.9) 1 (1.1) 13 (2.5) 223 (3.7) 78 (6.1) 301 (4.2)
Body weight (kg) 83.0 (19.2) 86.9 (22.9) 83.7 (20.0) 82.0 (18.6) 88.0 (20.1) 83.0 (19.0)




78.8 (20.1) 81.2 (22.5) 79.3 (20.5) 78.5 (20.5) 77.9 (21.2) 78.4 (20.7)
Haemoglobin (g/L) 139.2 (14.7) 136.0 (14.1) 138.6 (14.7) 137.2 (15.0) 136.1 (15.3) 137.0 (15.0)
LDL cholesterol (mmol/L) 2.0 (0.8) 2.1 (0.9) 2.0 (0.8) 2.0 (0.8) 2.1 (0.8) 2.1 (0.8)
Systolic blood pressure
(mmHg)
127.5 (17.2) 127.4 (17.0) 127.5 (17.1) 128.3 (17.6) 127.0 (16.8) 128.1 (17.5)
The baseline characteristics are displayed for patients included in the population pharmacokinetic analysis and in the pharmacodynamic analysis.





























































































































































































































































F IGURE 1 Aleglitazar exposure over time stratified by clopidogrel use (n = 514). Data are displayed as: Observations (○), mean population
prediction (−) with 95% prediction interval
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in the model. Aleglitazar exposure over time for the final pharmacoki-
netic model, stratified by clopidogrel use, is displayed in Figure 1. As
shown in Figure 1, the IIV in the pharmacokinetics of aleglitazar is well
described by the model, ie, 95% of the data points lie within the 95%
prediction interval of the model.
As covariates were identified on KA and CL/F, the population
pharmacokinetic model was used to estimate the time to maximal
concentration (tmax) and area under the plasma-concentration-time
curve (AUC0–24) at steady state. Overall, a fast absorption phase was
observed for aleglitazar with a median time to maximal concentration
of 1.17 (0.17–3.92) hours. After stratifying for food intake, the median
tmax was 1.17 (0.17–3.92) and 1.25 (0.17–3.42) hours for administra-
tion of aleglitazar in fasted and non-fasted condition, respectively.
The mean AUC0–24 for patients included in the pharmacokinetic sub-
study was 168.7 ng h/mL (SD: ±110.1 ng h/mL). After stratifying for
clopidogrel use, the mean predicted AUC0–24 was 142.2 ng h/mL (SD:
±92.6 ng h/mL) and 174.7 ng h/mL (SD: ±112.9 ng h/mL) in patients
treated without and with clopidogrel, respectively.
3.2 | Pharmacodynamic analysis
Because of a large unexplained variability in the population pharmaco-
kinetic model, aleglitazar exposure could not be estimated in the
remaining 3101 patients, for whom no pharmacokinetic samples were
collected. To include all patients in the pharmacodynamic analysis, we
assessed the effect of aleglitazar on cardiovascular risk markers and
clinical outcomes by concomitant clopidogrel administration, as this
was an important covariate in the population pharmacokinetic model
which explained variability in exposure. Aleglitazar has a direct effect
on body weight.5 Therefore, body weight was not explored in the
pharmacodynamic analysis as the statistical approach cannot separate
the difference between direct effects on response versus indirect
effects, mediated by exposure, on response. The demographics of the
patients included in the pharmacodynamic analysis are displayed in
Table 1. A total of 3020 patients out of 3616 patients (83.5%) treated
with aleglitazar used clopidogrel compared with 2932 patients out of
3610 patients (81.2%) treated with placebo.
3.2.1 | Surrogate outcomes
The absolute change in HbA1c, serum creatinine, haemoglobin, body
weight, adiponectin and triglycerides over time, stratified by treat-
ment and clopidogrel use, are displayed in Figure 2. The effect of
aleglitazar compared with placebo on HbA1c, haemoglobin, serum
creatinine and adiponectin was modified by concomitant clopidogrel
use (P for interaction 0.007, 0.002, <0.001 and <0.001, respectively;
Table 3). The direction of the interaction was such that aleglitazar
compared with placebo caused a larger reduction in HbA1c and
haemoglobin and a larger increase in serum creatinine and adiponectin
in patients who were concomitantly using clopidogrel versus patients
who were not. The effect of aleglitazar compared with placebo on
body weight and triglycerides was not modified by concomitant
clopidogrel use (P for interaction 0.434 and 0.318, respectively).
3.2.2 | Clinical outcomes
The influence of concomitant administration of clopidogrel with
aleglitazar on clinical outcomes is displayed in Figure 3. The effect of
aleglitazar compared with placebo on the risks of hospitalization for
heart failure was modified by clopidogrel use (P for interaction 0.01).
Specifically, aleglitazar caused an increased risk of hospitalization for
heart failure (HR: 1.21, 95% CI: 1.04–1.40) in patients with concomi-
tant clopidogrel use. Conversely, aleglitazar showed a trend for a
decreased risk of hospitalization for heart failure (HR: 0.78, 95% CI:
0.57–1.06) among patients without using clopidogrel. No effect modi-
fication by clopidogrel was observed for bone fractures or gastrointes-
tinal haemorrhage (Figure 3).
4 | DISCUSSION
A large variation between individuals was observed in the plasma con-
centrations of aleglitazar in the AleCardio trial. We found that the
plasma concentration-time profile of aleglitazar was best described
using a two-compartment model with first-order absorption, first-
order elimination and allometric scaling. Using this model, we showed
that part of the observed IIV could be attributed to a reduced




RSE (%) CV (%)
Cl/F Apparent clearance from central compartment (L h−1) 1.07 6.7 57.1
V2/F Apparent volume of distribution for central compartment (L) 1.23 13.7 587
Q/F Apparent intercompartmental clearance (L h−1) 2.16 19.0 N/E
V3/F Apparent volume of distribution for peripheral compartment (L) 8.40 4.2 N/E
KA First-order absorption rate constant (h−1) 0.508 15.5 N/E
Linear coefficient for non-fasted conditions on absorption rate constant 0.807 6.0 N/E
Linear coefficient for clopidogrel use on apparent clearance from central compartment 0.836 6.9 N/E
Proportional residual error 0.198 5.76 N/E
Abbreviations: CV, coefficient of variation; N/E, not estimated; RSE, relative standard error.











































































































































































































































































































































































Aleglitazar 150 ug without clopidogrel
Aleglitazar 150 ug with clopidogrel
F IGURE 2 Absolute change in cardiovascular risk markers over time in aleglitazar and placebo randomized patients stratified by baseline
clopidogrel use. A, HbA1c (%), B, serum creatinine (mg/dL), C, haemoglobin (g/L), D, body weight (kg), E, adiponectin (pmol/L), F, triglycerides
(mmol/L). Data are displayed as mean absolute change per study visit with 95% confidence intervals
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clearance of aleglitazar in patients using clopidogrel concomitantly.
The pharmacodynamic analysis revealed that patients receiving con-
comitant clopidogrel showed larger reductions in HbA1c and
haemoglobin and a larger increase in serum creatinine and adiponectin
compared with patients who did not use clopidogrel.
In this study we found that the observed variability between indi-
viduals in the plasma concentration-time profile of aleglitazar in the
AleCardio trial population, after administration of the therapeutic
150 μg/day aleglitazar dose, covered the complete dose range of
20–900 μg/day observed in a prior study of patients with type 2 dia-
betes mellitus.7 To better characterize the variability in the pharmaco-
kinetics of aleglitazar in the AleCardio trial population, a population
pharmacokinetic analysis was conducted. The developed two-
compartment model with first-order absorption and first-order elimi-
nation described the data best, which is in line with a previously
reported population pharmacokinetic analysis based on data from the
SYNCHRONY trial.8 Inclusion of a food effect on the absorption rate
constant and an effect of concomitant administration of clopidogrel
on the apparent clearance improved the overall model fit and
explained part of the IIV.
In the AleCardio population, tmax ranged from 0.2 to 3.9 hours,
which appears to be faster than previously reported in patients with
type 2 diabetes mellitus (ranging from 2.0 to 8.0 hours).7 The
population pharmacokinetic model identified a food effect on the
absorption rate constant that could partly explain the fast absorption.
Under fasting conditions, the absorption rate constant increased by
23.9%. The absorption phase of aleglitazar was estimated with high
precision (RSEs were 15.5% for KA and 6% for the food effect). None-
theless, to our knowledge, dedicated clinical studies on the food
effects of aleglitazar have not been published and therefore our
results, obtained from a post hoc analysis, should be carefully inter-
preted. Nevertheless, they are in line with a mass-balance study that
reported fast absorption under fasting conditions (tmax ranging from
0.47 to 1.0 hours).9 Alternatively, the fast absorption may be caused
by a formulation effect because the mass-balance study used an oral
aleglitazar solution.9
Co-medication that could potentially influence the pharmacoki-
netics of aleglitazar was investigated as a covariate in the population
pharmacokinetic model. Patients using both aleglitazar and clopidogrel
showed a 16.4% lower apparent clearance, which results in a higher
exposure to aleglitazar compared with patients solely treated with
aleglitazar (AUC0–24 of 174.7, SD 112.9 ng h/mL and 142.2, SD
92.6 ng h/mL, respectively). Clopidogrel is an antiplatelet drug and is
commonly prescribed in the treatment of ACS, which explains the
large number of patients receiving clopidogrel in the AleCardio
trial.10,11 The effect of clopidogrel on the apparent clearance of
TABLE 3 Effect of aleglitazar compared with placebo on cardiovascular risk markers according to baseline clopidogrel use
Surrogate Outcome With clopidogrel Without clopidogrel Difference P interaction
HbA1c (%) −0.72 (−0.64 to −0.80) −0.39 (−0.15 to −0.63) −0.33 (−0.09 to −0.57) 0.007
Serum creatinine (mg/dL) 0.14 (0.13 to 0.15) 0.07 (0.04 to 0.10) 0.06 (0.03 to 0.09) <0.001
Haemoglobin (g/L) −7.11 (−6.46 to −7.76) −3.78 (−1.74 to −5.82) −3.33 (−1.19 to −5.47) 0.002
Body weight (kg) 2.50 (2.28 to 2.72) 2.80 (2.09 to 3.51) −0.3 (0.44 to −1.04) 0.434
Adiponectin (pmol/L) 10 286.7 (9912.7 to 10 660.7) 6910.4 (5717.6 to 8103.2) 3376.31 (2126.2 to 4626.4) <0.001
Triglycerides (mmol/L) −0.66 (−0.61 to – 0.73) −0.57 (−0.38 to −0.76) −0.10 (0.09 to −0.30) 0.318
Data are displayed as placebo-corrected absolute change from baseline with aleglitazar to month 6 (mean difference with 95% CI).
F IGURE 3 Forest plot of safety findings of the AleCardio trial. The plot is stratified for all patients, patients using clopidogrel and patients not
using clopidogrel. The forest plot shows the mean hazard ratio including the 95% confidence interval
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aleglitazar may be explained by the metabolism of aleglitazar, which is
converted by CYP2C8 and CYP2C19 into metabolites M1 and M6.12
Clopidogrel is an inhibitor of CYP2C8 and thus may reduce the clear-
ance of aleglitazar.13 As plasma clopidogrel concentrations were not
available, no individual exposure of clopidogrel could be incorporated
in the model.
Only concomitant use of clopidogrel affected the exposure of
aleglitazar. High aleglitazar exposure caused by concomitant adminis-
tration of clopidogrel resulted in an additional beneficial effect on
HbA1c, an additional decrease in haemoglobin and an additional
increase in serum creatinine and adiponectin. The administration of
clopidogrel alone does not affect these surrogates as no differences in
these variables were observed in the placebo group between patients
treated with or without clopidogrel. The reduction in haemoglobin
probably reflects haemodilution from sodium and the fluid-retaining
effects of aleglitazar, while the increase in serum creatinine has been
shown to be completely reversible after cessation of aleglitazar and
reflects a renal haemodynamic effect.5
Our analysis also showed that patients with high aleglitazar expo-
sure caused by concomitant administration of clopidogrel showed an
increased risk of hospitalization for heart failure, whereas patients
without concomitant clopidogrel showed a trend towards a risk reduc-
tion. This finding supports the idea that a pharmacokinetic interaction
between aleglitazar and clopidogrel has contributed to the increased
exposure, resulting in a larger degree of sodium retention and
increased risk of edema and heart failure. Nonetheless, concomitant
use of clopidogrel did not explain the increased rates of gastrointesti-
nal events and bone fractures.
Overall, body weight increased with aleglitazar compared with pla-
cebo by a mean of approximately 4 kg at 24 months. Although there
may have been some contribution to increased body weight from fluid
retention, the major mechanism of weight gain with PPAR-γ agonists
is an increase in adipose tissue mass.14 We found no significant inter-
action of clopidogrel and aleglitazar treatment on body weight. This
neutral finding is unexplained, but might indicate that the aleglitazar
concentration-adipose tissue remodelling relationship was insensitive
to the changes in aleglitazar exposure induced by clopidogrel co-
treatment.
The phase II dose-finding trials aimed to determine the optimal
dose of aleglitazar and were conducted in patients with type 2 diabe-
tes mellitus without ACS. These studies concluded that the optimal
benefit/risk balance is achieved at a daily dose of 150 μg. The
AleCardio trial included patients with type 2 diabetes mellitus and
ACS. A majority of patients used clopidogrel in the AleCardio trial
because of a recent ACS, which contributed to a different aleglitazar
pharmacokinetic and pharmacodynamic profile in the phase III clini-
cal trial population. It is at this point unclear if a lower dose of
aleglitazar in the AleCardio trial could have resulted in a more
favourable benefit/risk balance as we were not able to estimate
aleglitazar exposure in all patients enrolled in the trial. Regardless,
the lesson to be taken from this study is that dose finding should
ideally be performed in the same population as the phase III clinical
trial population.
The results of this study may have clinical implications for future
and existing PPAR therapies. For example, it has been shown that the
area under the plasma concentration-time curve of pioglitazone, a
PPAR-γ agonist, increased 2.1-fold after administration of
clopidogrel.15 This suggests that a clinically relevant interaction may
be present between clopidogrel and pioglitazone. Further studies in
high cardiovascular risk patients using pioglitazone and clopidogrel,
such as those participating in the PROactive and IRIS cardiovascular
outcome trials, may indicate whether this interaction modifies the
effect of pioglitazone on biomarkers and clinical events.16,17
Although the population pharmacokinetic model allowed for accu-
rate description of the pharmacokinetic variables of patients included
in the pharmacokinetic substudy, the model showed some bias in the
structural model and a large unexplained IIV, mainly in the apparent
volume of distribution. This translated into an underprediction of the
plasma concentration of aleglitazar in the higher concentration range.
As such, the presented model was less useful for simulating the phar-
macokinetic profiles of the remaining 3101 patients exposed to
aleglitazar, for whom no pharmacokinetic data were available. Conse-
quently, a stratification strategy was applied for the pharmacodynamic
analysis on all patients, based on the main determinants for differ-
ences in exposure to aleglitazar. As a large IIV remained unexplained
in the population pharmacokinetic analysis, it cannot be excluded that
we missed important covariates which also significantly contribute to
the variability in exposure and response to aleglitazar. It is, therefore,
not possible to make definitive conclusions about if aleglitazar expo-
sure was related to other safety outcomes, including gastrointestinal
haemorrhages and bone fractures. To simulate pharmacokinetic data
of all individuals in phase III clinical trials, more informative pharmaco-
kinetic sampling schemes should be developed. Ideally, three samples
per slope of the absorption and elimination phases of the plasma
concentration-time profile should be obtained throughout a phase III
trial.
In conclusion, the population pharmacokinetic analysis of the
AleCardio trial identified concomitant administration of clopidogrel
and food effect as covariates that influence the pharmacokinetics of
aleglitazar. Concomitant administration of clopidogrel resulted in an
increased exposure of aleglitazar, an additional decrease in HbA1c—at
the expense, however, of an additional decrease in haemoglobin—and
an increase in serum creatinine and adiponectin. Clopidogrel is a mod-
erate inhibitor of the CYP2C8 enzyme, and as aleglitazar is partially
metabolized by the CYP2C8 enzyme, a pharmacokinetic interaction
could explain the observed differences between patients with and
without clopidogrel.
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